Carcinomatous meningitis: Leptomeningeal metastases in solid tumors

Surgical Neurology International

Volumn 4, Issue SUPPL4, 2013, Pages

  Le Rhun, Emilie ^a   Taillibert, Sophie ^b   Chamberlain, Marc ^c  

^a CENTRE OSCAR LAMBRET   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Diagnostic tools; leptomeningeal metastases; monoclonal antibody; neoplastic meningitis; solid tumors; targeted therapy; tyrosine kinase inhibitors

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CARBAMAZEPINE; CORTICOSTEROID; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GABAPENTIN; GEFITINIB; HYDROCORTISONE; IPILIMUMAB; LAMOTRIGINE; MACROSALB TC 99M; METHOTREXATE; MONOCLONAL ANTIBODY; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; PREGABALIN; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; THIOTEPA; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB;

ACUTE BRAIN DISEASE; ARACHNOIDITIS; ARTICLE; BACKACHE; BRAIN DISEASE; BRAIN PSEUDOTUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMATOUS MENINGITIS; CAUDA EQUINA SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; COMMUNICATING HYDROCEPHALUS; CONTINUOUS INFUSION; DRUG HALF LIFE; DRUG MEGADOSE; EARLY DIAGNOSIS; HEADACHE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MENINGEAL METASTASIS; NAUSEA; NERVE FIBER; NEUROIMAGING; NEUROLOGICAL COMPLICATION; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATIENT CARE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RADICULAR PAIN; RADICULOPATHY; RADIODIAGNOSIS; SEIZURE; SOLID TUMOR; SPINAL CORD DISEASE; VISUAL IMPAIRMENT;

EID: 84878002226     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.111304     Document Type: Article

References (301)

1. Adamson PC, Balis FM, Arndt CA, Holcenberg JS, Narang PK, Murphy RF, et al. Intrathecal 6-mercap- topurine: Preclinical pharmacology, phase I/II trial, and pharmacokinetic study. Cancer Res 1991;51:6079-83
2. Agarwal A, Vijay K, Thamburaj K, Ouyang T. Transient leukoencephalopathy after intrathecal methotrexate mimicking stroke. Emerg Radiol 2011;18:345-7
3. Ahn JH, Lee SH, Kim S, Joo J, Yoo H, Lee SH, et al. Risk for leptomeningeal seeding after resection for brain metastases: Implication of tumor location with mode of resection. J Neurosurg 2012;116:984-93
4. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007;110:2640-7
5. Aradillas E, Arora R, Gasperino J, Methotrexate-induced posterior reversible encephalopathy syndrome. J Clin Pharm Ther 2011;36:529-36
6. Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, et al. Regional treatment of epidermal growth factor receptor vIII- expressing neoplastic meningitis with a single-chain immunotoxin, MR-I. Clin Cancer Res 1999;5:2646-52
7. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989;11:74-86
8. Balm M, Hammack J, Leptomeningeal carcinomatosis: Presenting features and prognostic factors. Arch Neurol 1996;53:626-32
9. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7
10. Benjamin JC, Moss T, Moseley RP, Maxwell R, Coakham HB. Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody. Neurosurgery 1989;25:253-8
11. Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Sato J, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992;10:143-8
12. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010;16:269-78
13. Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, et al. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin Cancer Res 1995;1:1545-55
14. Blaney S, Balis F, Murphy RF, Arndt CA, Gillepsie A, Poplack DG. A phase I study of intrathecal mafosfamide (MF) in patients with refractory meningeal malignancies, Abstract 274. Am Soc Clin Oncol 1992;11:113
15. Blaney S, Poplack D, Godwin K, McCully C, Murphy RF, Balis F. The effect of body position on ventricular cerebrospinal fluid methotrexate following intralumbar administration. J Clin Oncol 1995;13:177-9
16. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003;21:143-7
17. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975;195:73-83
18. Bleyer WA, Drake J, Chabner B. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-3
19. Bleyer WA, Poplack DG, Simon RM. ′′Concentration- time′′ methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978;51:835-42
20. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases in solid tumors: Exclusion of intra-CSF chemotherapy does not affect treatment outcome. Comparison of two prospective series. Neurology 1997;48:A35
21. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: A comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998;82:1756-63
22. Boogerd W, vd Sande JJ, Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 1988;51:1277-83
23. Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer.Prognostic factors and influence of treatment. Cancer 1991;67:1685-95
24. Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000;55:117-9
25. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: A randomised study. Eur J Cancer 2004;40:2726-33
26. Bot I, Blank CD, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 2012;259:1976-8
27. Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by tumour: A clinical and pathological study of 63 cases. Postgrad Med J 1980;56:149-58
28. Brandsma D, Reijneveld JC, Taphoorn MJ, de Boer HC, Gebbink MF, Ulfman LH, et al. Vascular cell adhesion molecule-1 is a key adhesion molecule in melanoma cell adhesion to the leptomeninges. Lab Invest 2002;82:1493-502
29. Brandsma D, Voest EE, de Jager W, Bonfrer H, Algra A, Boogerd W, et al. CSF protein profiling using Multiplex Immuno-assay: A potenteoal new diagnostic tool for leptomeningeal metastases. J Neurol 2006;253:1177-84
30. Braen AP, Perron J, Tellier P, Catala AR, Kolaitis G, Geng W. A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys. Int J Toxicol 2010;29:259-67
31. Brastianos PK, Brastanios HC, Hsu W, Sciubba DM, Kosztowski T, Tyler BM, et al. The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. J Neurooncol 2012;106:81-8
32. Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain MC, et al. Central nervous system cancers: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005;3:644-90
33. Brem SS, Bierman PJ, Brem H, Buiowski N, Chamberlain MC, Chiocca EA, et al. National Comprehensive Cancer Network, Central nervous system. J Natl Compr Canc Netw 2011;9:352-400
34. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon, Reiman R, et al. Intrathecal 131 I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 1996;2:963-72
35. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83
36. Burch PA, Grossman SA, Reinhard CS. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: A quantitative autoradiographic study. J Natl Cancer Inst 1988;80:1211-6
37. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983;1:313-7
38. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990;40:435-8
39. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991;41:1765-9
40. Chamberlain MC, Dirr L. Involved-field radiotherapy and intra-Ommaya methotrexate/cytarabine in patients with AIDS-related lymphomatous meningitis. J Clin Oncol 1993;11:1978-84
41. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 1993;50:261-4
42. Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996;46:1674-7
43. Chamberlain M, Kormanik P. Leptomeningeal metastases due to melanoma. Int J Oncol 1996;9:505-10
44. Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 1997;54:1364-8
45. Chamberlain MC, Kormanik PR. Carcinomatous meningitis secondary to breast cancer: Predictors of response to combined modality therapy. J Neurooncol 1997;35:55- 64
46. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 1998;38:135-40
47. Chamberlain M. Leptomeningeal metastases: A review of evaluation and treatment. J Neurooncol 1998;37:271-84
48. Chamberlain MC. Cytologically negative carcinomatous meningitis: Usefulness of CSF biochemical markers. Neurology 1998;50:1173-5
49. Chamberlain MC, Kormanik P. Carcinomatous meningitis secondary to nonsmall cell lung cancer: Combined modality therapy. Arch Neurol 1998;55:506-12
50. Chamberlain MC, Kormanik P, Jaeckle KA, Glantz M. 111Indium- diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999;52:216-7
51. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro-Oncology 2001;3:42-5
52. Chamberlain MC. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2001;56:425-6
53. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 2002;94:2675-80
54. Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 2003;52:324-9
55. Chamberlain MC. Neoplastic meningitis: Deciding who to treat. Expert Rev Neurother 2004;4:89-96
56. Chamberlain MC, Tsao-Wei D, Groshen S. Neoplastic meningitis-related encephalopathy: Prognostic significance. Neurology 2004;63:2159-61
57. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 2006;106:2021-7
58. Chamberlain MC. Neoplastic meningitis. Oncologist 2008;13:967-77
59. Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol 2009;66:74-8
60. Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for neoplastic meningitis: Detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009;36:S35-45
61. Chamberlain MC, Johnston SK. Neoplastic meningitis: Survival as a function of cerebrospinal fluid cytology. Cancer 2009;115:1941-6
62. Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol 2010;22:627-35
63. Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: A retrospective case series. J Neurooncol 2012;109:143-8
64. Chamberlain MC. Neuraxis imaging in leptomeningeal metastasis: A retrospective case series. CNS Tumors 2046 J Clin Oncol 2012;30 (abstr 2046)
65. Champagne MA, Silver HK. Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma. J Natl Cancer Inst 1992;84:1203-4
66. Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep 2003;5:24-8
67. Chen YM, Chen MC, Tsai CM, Perng RP. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis: A case report. Lung Cancer 2003;40:99-101
68. Chen J, Balmaceda C, Bruce JN, Sisti MB, Huang M, Cheung YK, et al. Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J Neurooncol 2006;76:85-92
69. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-7
70. Chuang TY, Yu CJ, Shih JY, Yang PC, Kuo SH. Cytologically proven meningeal carcinomatosis in patients with lung cancer: Clinical observation of 34 cases. J Formos Med Assoc 2008;107:851-6
71. Clamon G, Boebbeling B. Meningeal carcinomatosis from breast cancer: Spinal vs brain involvement. Breast Cancer Res Treat 1987;9:213-7
72. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99:283-6
73. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology 2010;74:1449-54
74. Clatot F, Philippin-Lauridant G, Ouvrier MJ, Nakry T, Laberge-Le-Couteulx S, Guillemet C, et al. Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol 2009;95:421-6
75. Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using (131) I-radiolabelled monoclonal antibodies, results of responses and long term follow-up in 40 patients. J Neurooncol 1998;38:225-32
76. Cokgor I, Akabani G, Friedman HS, Friedman AH, Zatusky MR, Zehngebot LM, et al. Long term response in a patient with neoplastic meningitis secondary to melnoma treated with (131) I-radiolabeled ant chondroitin proteoglycan sulfate Mel-14 F(ab′) (2): A case study. Cancer 2001;91:1809-13
77. Cokgor I, Friedman AH, Friedman HS. Current options for the treatment of neoplastic meningitis. J Neurooncol 2002;60:79-88
78. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003;97:3053-60
79. Corsini E, Bernardi G, Gaviani P, Silvani A, de Grazia U, Ciusani E, et al. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med 2009;47:874-9
80. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001;12:353-6
81. D′Angio GJ, French LA, Stadlan EM, Kieffer SA. Intrathecal radioisotopes for the treatment of brain tumors. Clin Neurosurg 1968;15:288-300
82. DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fiks Z, et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989;24:798-805
83. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998;38:245-52
84. de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, et al. Meningeal carcinomatosis in breast cancer: Prognostic factors and outcome. J Neurooncol 2011;104:565-72
85. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100:443-7
86. Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 2005;4:1341-9
87. Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: Response to high-dose erlotinib. J Clin Oncol 2009;27:e31-2
88. Dicuonzo F, Salvati A, Palma M, Lefons V, Lasalandra G, De Leonardis F, et al. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: Conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol 2009;24:1013-8
89. Dietemann JL, Correia Bernardo R, Bogorin A, Abu Eid M, Koob M, Nogueira T, et al. Normal and abnormal meningeal enhancement: MRI features. J Radiol 2005;86:1659-83
90. Dinndorf PA, Bleyer WA. Management of infectious complications of intraventricular reservoirs in cancer patientsq: Low incidence and successful treatment without reservoir removal. Cancer Drug Deliv 1987;4:105-17
91. Doge H, Hliscs R. Intrathecal therapy with 198Au-colloid for meningosis prophylaxis. Eur J Nucl Med 1984;9:125-8
92. Donehower R, Karp J, Burke P. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986;70:1059-65
93. Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, Veronese L, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases 8548. J Clin Oncol 2011;29 suppl, abstr 8548
94. Dux R, Kindler-Röhrborn A, Annas M, Faustmann P, Lennartz K, Zimmerman CW. A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid. J Neurol Sci 1994;121:74-8
95. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007;85:223-7
96. Elliott JP, Keles GE, Waite M, Temkin N, Berger MS. Ventricular entry during resection of malignant gliomas: Effect on intracranial cerebrospinal fluid tumor dissemination. J Neurosurg 1994;80:834-9
97. Esteva FJ, Soh LT, Holmes FA, Plunket W, Meyers CA, Forman AD, et al. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 2000;46:382-6
98. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012;379:1893-901
99. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009;20:792-5
100. Fishman RA. Cerebrospinal fluid in diseases of the nervous system. 2 nd ed. Philadelphia: W.B. Saunders Company; 1992
101. Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, et al. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996;77:1315-23
102. Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 2001;84:1453-9
103. Frick J, Ritch PS, Hansen RM, Anderson T. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 1984;2:365-8
104. Fulton DS, Levin VA, Gutin PH, Edwards MS, Seager ML, Stewart J, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 1982;8:285-91
105. Gallego Perez-Larraya J, Palma JA, Carmona-Iragui M, Fernandez-Torron R, Irimia P, Rodrguez-Otero P, et al. Neurologic complications of intrathecal liposomal cytarabine administered prophylactic ally to patients with non- Hodgkin′s lymphoma. J Neurooncol 2010;103:603-9
106. Gani C, Müller AC, Eckert F. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis form solid tumors. Strahlenther Oncol 2012;188:148-53
107. Gaucher AS, Pez E, Boutonnat J, Bourre JC, Pelleter L, Payan R, et al. Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: Validation of CA 15-3 measurement in cerebrospinal fluid. Ann Biol Clin 2007;65:653-8
108. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 2010;21:2183-7
109. Geldof AA. Models for cancer skeletal metastasis: A reappraisal of Batson′s plexus. Anticancer Res 1997;17:1535-9
110. Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 2003;65:167-72
111. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995;75:2919-31
112. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results. Cancer 1998;82:733-9
113. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary?. J Clin Oncol 1998;16:1561-7
114. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-402
115. Glantz MJ, LaFollette S, Jaeckle K. Randomized trial of a slow- release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17:3110-6
116. Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010;116:1947-52
117. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. Neurology 1979;29:1369-75
118. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol 2006;5:443-52
119. Gonzalez-Vitale JC, Garcia-Bunuel R. Meningeal carcinomatosis. Cancer 1976;37:2906-11
120. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994;51:457-61
121. Grewal J, Saria MG, Kesari S. Novel approaches to treating leptomeningeal metastases. J Neurooncol 2012;106:225-34
122. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodony AI, et al. «Pulsatile» high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011;13:1364-9
123. Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 1982;73:641-7
124. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis, Eastern Cooperative Oncology Group. J Clin Oncol 1993;11:561-9
125. Groves MD. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2006;66:1609-10
126. Groves MD, Glantz MJ, Chamberlain MC. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 2008;10:1010-8
127. Groves MD. Advances in treating leptomeningeal metastases, Educational Book. Alexandria, Virginia: American Society of Clinical Oncology; 2008. p. 80-7
128. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, et al. Biomarkers of disease: Cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009;94:229-34
129. Groves MD. New strategies in the management of leptomeningeal metastases. Arch Neurol 2010;67:305-12
130. Groves MD. Leptomeningeal disease. Neurosurg Clin North Am 2011;22:67-78
131. Groves MD, DeGroot J, Tremont I, Forman A, Kang S, Pei BL, et al. A pilot study of systemically administered bevacizumab with neoplastic meningitis NM: Imaging, clinical, CSF and biomarker outcomes. Neuro Oncol (OT-02) 2011;13:iii85-91
132. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Philips PC, Friedman HS, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: A Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res 2006;12:1540-6
133. Gütling E, Landis T, Kleihues P. Akinetic mutism in bilateral necrotizing leucoencephalopathy after radiation and chemotherapy: Electrophysiological and autopsy findings. J Neurol 1992;239:125-8
134. Hall WA, Fodstad O. Immunotoxins and central nervous system neoplasia. J Neurosurg 1992;76:1-12
135. Hammerer V, Pauli G, Quoix E. Retrospective study of a series of 26 carcinomatous meningitis secondary to lung cancer. Bull Cancer 2005;92:989-94
136. Hansen K, Gjerris F, Sorensen PS. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir (Wien) 1987;86:93-7
137. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. J Neurooncol 2008;10:1010-8
138. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer 2006;53: 387-90
139. Hata A, Katakami N, Kaji R, Fujita S, Imai Y. Erlotinib for whole-brain-radiotherapy-refractory leptomeningeal metastases after gefitinib failure in a lung adenocarcinoma patient. J Thorac Oncol 2012;7:770-1
140. Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol 1998;38:233-9
141. Herrlinger U, Fösrschier H, Küker W, Meyermann R, Bamberg M, Dichgans J, et al. Leptomeningeal metastasis: Survival and prognosis in 155 patients. J Neurol Sci 2004;223:167-78
142. Hiesiger EM, Picco-Del Bo A, Lipschutz LE, Basler GA, Thaler HT, Posner JB, et al. Experimental meningeal carcino-matosis selectively depresses local cerebral glucose utilization in rat brain. Neurology 1989;39:90-5
143. Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, et al. Neurological complications after intrathecal liposomal cytarabine application in patients after allogenic hematopoietic stem cell transplantation. Ann Hematol 2008;87:1009-12
144. Hisanaga M, Kawai S, Maekawa M, Hattori Y, Kotoh K. Neoplastic aneurysms due to cerebral metastasis of choriocarcinoma. Report of two cases. Neurol Med Chir (Tokyo) 1988;28:398-403
145. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5:1655-62
146. Hoang-Xuan K, Napolitano M, Cornu P, Delattre JY. Metastases cerebrales et leptomeningees des cancers solides (French). Encyclopédie Medico Chirurgicale (Elsevier, Paris), Neurologie 1999;17-225-A-210
147. Hofer S, Mengele K, Stemmler HJ, Schmitt M, Pestalozzi B. Intrathecal trastuzumab: Dose matters. Acta Oncol 2012;51:955-6
148. Jabbour E, O′Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;109:3214-8
149. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al. Response and resistance in a non-small cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517-20
150. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001;84:157-63
151. Jaeckle KA, Neoplastic meningitis from systemic malignancies: Diagnosis, prognosis, and treatment. Semin Oncol 2006;33:312-23
152. Jayson GC, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 1994;74:3135-41
153. Jiménez Mateos A, Cabrera Naranjo F, González Hernández A, Fabre Pi O, Díaz Nicolás S, López Fernández JC. Neoplastic meningitis. Review of a clinical series. Neurologia 2011;26:227-32
154. Johnson VG, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield EH, et al. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 1989;70:240-8
155. Kanaji N, Bandoh S, Nagamura N, Kushida Y, Haba R, Ishida T. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Internal Med 2007;46:1651-5
156. Kang SJ, Kim KS, Ha YS, Huh SY, Lee JH, Kim JK, et al. Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis. J Clin Neurol 2010;6:33-7
157. Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, et al. Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;9:225-9
158. Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415-9
159. Kemshead JT, Papanastassiou V, Coakham HB, Pizer BL. Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer 1992;28:511-3
160. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003;21:25-66
161. Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993;11:2186-93
162. Kim DY, Lee KW, Yun T, Park SR, Jung JY, Kim DW, et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: Methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 2003;33:608-12
163. Kim KH, Im SA, Keam B. Clinical outcomes of central nervous system metastases from breast cancer: Differences in survival depending on systemic treatment. J Neurooncol 2012;106:303-13
164. Klein P, Haley EC, Wooten GF, Van den Berg SR. Focal cerebral infarctions associated with perivascular tumor infiltrates in carcinomatous leptomeningeal metastases. Arch Neurol 1989;46:1149-52
165. Koch D. Spinal metastases of cerebral glioma. Case report. Neurosurg Rev 1996;19:201-3
166. Kokkoris CP. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid?. Cancer 1983;51:154-60
167. Kramer K, Cheung NK, Humm JL, Dantis E, Finn R, Yeh SJ, et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131) I- 3F8. Med Pediatr Oncol 2000;35:716-8
168. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101:810-6
169. Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med 1991;115:507-10
170. Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study. J Surg Oncol 1991;48:28-33
171. Larson SM, Schall GL, Di Chiro G. The influence of previous lumbar
172. Lashfford LS, Davies AG, Richardson RB, Bourne SP, Bullimore JA, Eckert H, et al. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 1988;61:857-68
173. Laske DW, Muraszko KM, Oldfield EH, DeVroom HL, Sung C, Dedrick RL, et al. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 2007;41:1039-49
174. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006;78:255-60
175. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001;2:235
176. Lee S, Ahn HK, Park YH, Nam do H, Lee JI, Park W, et al. Leptomeningeal metastases from breast cancer: Intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treatment 2011;129:809-17
177. Le Rhun E, Taillibert S, Zairi F, Devos P, Pierret MF, Dubois F, et al. Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: A case-control study. J Neurooncol 2011;105:309-15
178. Levin VA, Chamberlain M, Silver P, Rodriguez L, Prados M. Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 1989;23:301-7
179. Liaw CC, Ng KT, Huang JS, Wang CH, Kiu MC, Lai GM, et al. Meningeal carcinomatosis from solid tumors: Clinical analysis of 42 cases. J Formos Med Assoc 1992;91:299-303
180. Lin M, Chen ZQ, Bao Y, Li Q, Du ZG, Xu ZD, et al. Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis. Zhonghua Bing Li Xue Za Zhi 2010;39:372-6
181. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 2008;113:2638-45
182. Lin NU. Concordance of HER2 in primary tumor and leptomeningeal metastases: Now what?. Breast Cancer Research Treat 2010;123:129-31
183. Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: A retrospective, case-controlled study. J Neurosurg 2011;115:730-6
184. List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA. Cytokine responses to intraventricular injection of interleu-kin 2 into patients with leptomeningeal carcinomatosis: Rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res 1992;52:1123-8
185. Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 1974;30:138-43
186. MacDonald D, Cascino T, Schold SJ, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80
187. Machado M, Salcman M, Kaplan RS, Montgomery E. Expanded role of the cerebrospinal fluid reservoir in neurooncology: Indications, causes of revision, and complications. Neurosurgery 1985;17:600-3
188. Madow L, Alpers BJ. Encephalitic form of metastatic carcinoma. AMA Arch Neurol Psychiatry 1951;65:161-73
189. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label phase 2 trial. Lancet Oncol 2012;13:459-65
190. Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998;50:438-44
191. Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 2011;67:1465-9
192. Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, et al. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast 2011;20:478-80
193. Mellett LB. Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 1977;61:527-31
194. Metz O, Stoll W, Plenert W. Meningosis prophylaxis with intrathecal 198Au-colloid and methotrexate in childhood acute lymphocytic leukemia. Cancer 1982;49:224-8
195. Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008;19:1978-80
196. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 1989;7:1701-9
197. Mittl RL Jr, Yousem DM. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. Am J Neuroradiol 1994;15:633-8
198. Morra E, Lazzarino M, Brusamolino E, Pagnucco G, Castagnola C, Bernasconi P, et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 1993;72:439-45
199. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012;7:382-5
200. Moseley RP, Davies AG, Richardson RB, Zalutsky M, Carrell S, Fabre J, et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer 1990;62:637-42
201. Moseley RP, Benjamin JC, Ashpole RD, Sullivan NM, Bullimore JA, Coakham HB, et al. Carcinomatous meningitis: Antibody-guided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry 1991;54:260-5
202. Moser AM, Adamson PC, Gillespie AJ, Poplack DG, Balis FM. Intraventricular Concentration times time (CxT) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 1999;85:511-6
203. Myklebust AT, Godal A, Fodstad O. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer. Cancer Res 1994;54:2146-50
204. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20
205. Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: A potentially preventable complication. J Neurooncol 1997;32:215-23
206. Novak LJ. Radiotherapy of the central nervous system in acute leukemia. Am J Pediatr Hematol Oncol 1989;11:87-92
207. Obbens EA, Leavens ME, Beal JW, Lee YY. Ommaya reservoirs in 387 cancer patients: A 15-year experience. Neurology 1985;35:1274-8
208. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: A retrospective analysis. J Cancer Res Clin Oncol 2010;136:1729-35
209. Ojeda VJ. Necrotising leucoencephalopathy associated with intrathecal/intraventricular methotrexate therapy. Med J Aust 1982;2:289-93
210. Oliveira M, Braga S, Passos-Coelho JL, Fonseca R, Oliveira J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 2011;127:841-4
211. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974;30:122-37
212. Omuro AM, Kris MG, Miller VA, Franchesci E, Shah N, Milton DT, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103:2344-8
213. Orphanos G, Ardavanis A. Leptomeningeal metastases from prostate cancer: An emerging clinical conundrum. Clin Exp Metastasis 2010;27:19-23
214. Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U, Neurological complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol 2010;103:635-40
215. Ozdogan M, Samur M, Bozcuk HS, Sagtas E, Yildiz M, Artac M, et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: A case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 2003;33:229-31
216. Pace P, Fabi A. Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 2006;60:528-34
217. Park IH, Kwon Y, Ro JY, Lee KS, Ro J. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue. Breast Cancer Res Treat 2010;123:125-8
218. Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-92
219. Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2011;2:752-60
220. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51
221. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51
222. Petit T, Dufour P, Korganov AS, Maloisel F, Oberling F. Continuous intrathecal perfusion of methotrexate for carcinomatous meningitis with pharmacokinetic studies: Two case studies. Clin Oncol 1977;9:189-90
223. Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases-treatment results in 98 consecutive patients. Israel J Med Sci 1988;24:611-8
224. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006;7:778-80
225. Poplack D, Bleyer WA, Horowitz M. Pharmacology of antineoplastic agents in cerebrospinal fluid. New York: Plenum Press; 1980
226. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol 1978;19:579-92
227. Posner JB. Leptomeningeal metastases in Neurologic Complications of Cancer. Philadelphia: F.A. Davis Company: 1995. p. 143-71
228. Price R, Jamieson P. The central nervous system in chidhood leukemia. Subacute leukoencephalopathy. Cancer 1975;35:306-18
229. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro Oncol 2008;10:199-207
230. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32
231. Regierer AC, Stroux A, Kühnardt D, Dieing A, Lehenbauer-Dehm S, Flath B, et al. Contrast-enhancing meningeal lesions are associated with onger survival in breast cancer related leptomeningeal metastasis. Breast Care (Basel) 2008;3:118-23
232. Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest 2003;33:76-81
233. Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005;65:1120-2
234. Renbarger J, Aleksic A, McGuffey L, Dauser R, Berg S, Blaney S. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 2004;53:39-42
235. Robins HI, Liu G, Hayes L, Mehta M. Trastuzumab for breast cancer-related carcinomatous meningitis. Clinical Breast Cancer 2002;2:316
236. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011;365:2439-41
237. Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol 2004;6:63-4
238. Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: Findings on diffusion-weighted imaging and correlation with clinical outcome. Am J Neuroradiol 2004;25:1688-95
239. Römpp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, et al. Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nano LC-FTICR MS. Proteomics 2007;7:474-81
240. Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, et al. Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 1982;61:45-53
241. Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis: The role of multimodality treatment. J Neurooncol 2007;84:57-62
242. Sakai M, Ishikawa S, Ito H, Ozawa Y, Yamamoto T, Onizuka M, et al. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol 2006;11:243-5
243. Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: Sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphasis Tumor Immunol 1993;13:49-54
244. Sause WT, Crowley J, Eyre HJ, Rivkin SE, Pugh RP, Quagliana JM, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases: A Southwest Oncology Group study. J Neurooncol 1988;6:107-12
245. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998;42:1044-56
246. Schumacher M, Orszagh M. Imaging techniques in neoplastic meningiosis. J Neurooncol 1998;38:111-20
247. Segura PP, Gil M, Balana C, Chacon I, Langa JM, Martin M, et al. Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. J Neurooncol 2012;109:137-42
248. Shapiro WR, Young DF, Mehta BM. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293:161-6
249. Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF. Treatment of meningeal neoplasms. Cancer Treat Rep 1977;61:733-43
250. Shapiro WR, Johanson CE, Boogerd W. Treatment modalities for leptomeningeal metastases. Semin Oncol 2009;36:S46-54
251. Shi Q, Pu CQ, Huang XS, Tian CL, Cao XT. Optimal cut-off values for tumor markers in cerebrospinal fluid with ROC curve analysis. Front Biosci (Elite Ed) 2011;3:1259-64
252. Shigekawa T, Takeuchi H, Misumi M, Matsuura K, Sano H, Fujiuchi N, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: A case report. Breast Cancer 2009;16:88-92
253. Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol 2011;6:1215-20
254. Siddiqui F, Marr L, Weissman DE, Neoplastic meningitis # 135. J Palliat Med 2009;12:88-9
255. Siegal T, Mildworf B, Stein D, Melamed E. Leptomeningeal metastases: Reduction in regional cerebral blood flow and cognitive impairment. Ann Neurol 1985;17:100-2
256. Siegal T, Pfeffer MR, Steiner I. Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery 1988;22:97-100
257. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: Analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994;44:1463-9
258. Siegal T. Leptomeningeal metastases: Rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998;38:151-7
259. Siegal T. Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep 2003;5:41-9
260. Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): A case report. J Med Case Rep 2012;6:131
261. Singh SK, Leeds NE, Ginsberg LE. Imaging of leptomeningeal metastases: Comparison of three sequences. Am J Neuroradiol 2002;23:817-21
262. Slavc I, Schuller E, Falger J, Günes M, Pillwein K, Czech T, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n=26) and etoposide (n=11): Experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003;64:239-47
263. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983;1:546-51
264. So T, Inoue M, Chikaishi Y, Nose N, Sugio k, Yasumoto K. Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: Report of two cases. Surg Today 2009;39:598-602
265. Soffietti R, Akerley W, Jensen RL, Bischoff J, Regierer AC. The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. Semin Oncol 2009;36:S55-68
266. Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lässig D, et al. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2- overexpressing metastatic breast cancer. Oncol Rep 2006;15:1373-7
267. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-8
268. Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Hermann KA, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER-2 overexpressing metastatic breast cancer: A case report. Anticancer Drugs 2008;19:832-6
269. Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Mulgg A, Kiechl S, et al. Vascular endothelial growth factor in CSF: A biological marker for carcinomatous meningitis. Neurology 2000;54:1670-6
270. Strazielle N, Khuth ST, Ghersi-Egea JF. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv Drug Deliv Rev 2004;56:1717-40
271. Strong JM, Collins JM, Lester C, Poplack DG. Pharmacokinetics of intraventricular and intravenous N, N′, N′′-triethylenethi- ophosphoramide (thiotepa) in rhesus monkeys and humans.Cancer Res 1986;46:6101-4
272. Sudo J, Hnmuora Y, Kurimoto F, Komagata H, Sakai H, Yoneda S. Meningela carcinomatosis in patients with lung cancer. Nihon Kokyuki Gakkai Zasshi 2006;44:795-9
273. Sundaresan N, Suite ND. Optimal use of the Ommaya reservoir in clinical oncology. Oncology (Huntingt) 1989;3:15-22
274. Sze G, Soletsky S, Bronen R, Krol G. MR Imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. Am J Roentgenol 1989;153:1039-49
275. Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: A case report. Clin Breast Cancer 2006;7:164-6
276. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: A review. J Neurooncol 2005;75:85-99
277. Teh HS, Fadilah SAW, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. Singapore Med J 2007;48: e46-9
278. Tetsumoto S, Osa A, Kijima T, Minami T, Hirata H, Takahashi R, et al. Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol 2012;17:155-9
279. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol 1981;38:696-9
280. Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, et al. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature. Lung Cancer 2012;77:464-8
281. Trump DL, Grossman SA, Thompson G, Murray K. CSF infections complicating the management of neoplastic meningitis. Clinical features and results of therapy. Arch Intern Med 1982;142:583-6
282. Tufekci O, Yilmaz S, Karapinar TH, Gozmen S, Cakmakci H, Hiz S, et al. A rare complication of intrathecal methotrexate in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2011;28:517-22
283. Turpin A, Pannier D, Zairi F, Cazin JL, Bonneterre J, Le Rhun E. Interest of a second line treatment with intrathecal thiotepa in the treatment of breast cancer leptomeningeal metastases (French). Journées de Neurologie de Langue Française, Nice 2012
284. van de Lagerijt B, Gijtenbeek JM, de Reus HP, Sweep FC, Geurts-Moespot A, Hendricks JC, et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 2006;67:114-9
285. van der Ree TC, Dippel DW, Avezaat CJ, Sillevis Smitt PA, Vecht CJ, van den Bent MJ. Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry 1999;66:225-7
286. van Zanten AP, Twijnstra A, Ongerboer de Visser BW, van Heerde P, Hart AA, Nooyen WJ. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry 1991;54:119-23
287. Wagner M, Besse B, Balleyguier C, Soria JC. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. J Thorac Oncol 2008;3:677-9
288. Waki F, Masashi A, Takashima A, Yonemori K, Nokihara H, Miyake M, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol 2009;93:205-12
289. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982;49:759-72
290. Wasserstrom WR. Leptomeningeal metastases, In: Wiley RG, editor. Neurological Complications of Cancer. New York: Marcel Dekker; 1995. p. 45-71
291. Waters KD. Leucoencephalopathy in patients on methotrexate. Lancet 1978;2:46
292. Weber JS, Amin A, Minor D, Siegel J, Berman D, O′Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: Retrospective analysis of data from a phase 2 trial. Melanoma Res 2011;21:530-4
293. Wen PY, Macdonald DR, Reardon DA, Cloughesy A, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72
294. Weston CL, Glantz MJ, Connor Jr. Detection of cancer cells in the cerebrospinal fluid: Current methods and future directions. Fluids Barriers CNS 2011;8:14
295. Witham TF, Fukui MB, Meltzer CC, Burns R, Kondziolka D, Bozik ME. Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Cancer 1999;86:1347-53
296. Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009;65:80-4
297. Youle RJ. Immunotoxins for central nervous system malignancy. Semin Cancer Biol 1996;7:65-70
298. Zairi F, Kotecki N, Rodrigues I, Baranzelli MC, Andre C, Dubois F, et al. Prospective follow-up of a cohort of 112 patients with leptomeningeal metastases of breast cancer recruited from 2007 to 2011: Prognostics factors. General Poster Session, Central Nervous System, abstract 2070, American Society of Clinical Oncology, Annual Meeting, 2012; June, Chicago, IL. J Clin Oncol 2012:30
299. Zhuang Y, Fraga CH, Hubbard KE, Hagedomm N, Panetta JC, Waters CM, et al. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 2006;66:11305-13
300. Zimm S, Collins JM, Miser J, Chatterji D, Poplack D. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 1984;35:826-30
301. Zovickian J, Youle RJ. Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. J Neurosurg 1988;68:767-74.